Ernst & Young published its 25th annual report - Beyond borders: Global biotechnology report - 2011. in it, E&Y cited India's biotech as hitting $4 B in 2010 compared to about $3 B in 2009. Vaccines, diagnostics and devices and personalized medicine were seen as the innovative growth areas. But, while the overall industry grew, most of that growth came from large firms while small firms fell back and continued to struggle to get investor funding.
"The domestic biotech firms wil need to adapt creatively to this environment by doing more with the funding that is available [ed. Pull on those bootstraps!] and by working from the earliest stages of development to demonstrate the potential value of their products to investors, payers and regulators, " said Ajit Mahadevan E&Y partner. See Fierce Biotech.
Sounds like some small guys will fail or be snapped up by the larger guys for a pittance as the industry goes through a shakeout of the weaker players.
Posted by Bruce Lehr Aug 30th 2011.
Comments